Microsoft word - poulin yves publications

Yves Poulin. PUBLICATIONS UP TO APRIL 2013:
Book chapters
Furger P. Médecine Interne: du symptôme au diagnostic. Transcontinental Metrolitho, 2005, First edition. Furger Dermatology P. Guide médical: Urgences et Diagnostic différentiel. Transcontinental Metrolitho, 2003, First edition. Dermatology chapter.
Peer-reviewed articles: 104 publications as of May 2013
104. Papp K, Poulin Y, Vieira A Examining the risk of cardiovascular disease in patients with psoriasis: a critical review.
J Cutan Med Surg. 2013 Mar-Apr;17(2):89-105.
103. Papp K, Poulin Y, Vieira A, Shelton J, Poulin-Costello M. Diseaase characteristics in patients with and without psoriatic arthritis
treated with etanercept. J Eur Acad Dermatol Venereol 2013 Mar 7. doi: 10.1111/jdv.12138. [Epub ahead of print]
102. Poulin Y, Wasel N,, Chan D, Bernstein G, Andrew R, Fraquelli E, Papp K. Evaluating practice patterns for managing moderate to
severe psoriasis: Role of the family physician. Can Fam Physician. July 2012;58(7) :e390-400
101. Tan J, O'Toole A, Zhang X, Dreno B, Poulin Y. Evaluation of the French version of the 4-item index of the Acne-QoL (AcneQ4fr)
Qual Life Res. 2012 Apr 28. [Epub ahead of print]
100. Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment vs. continuous therapy with
adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study, J Eur Acad Dermatol Venereol. 2012 Mar
16. doi: 10.1111/j.1468-3083.2012.04515.x. [Epub ahead of print]
99. Albrecht L, Bourcier M, Ashkenas J, Papp K; Canadian Psoriasis Guidelines Committee. Topical psoriasis therapy in the age of
Biologics: evidence-based treatment recommendations. J Cutan Med Surg. 2011 Nov-Dec;15(6):309-21
98. Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy and safety of topical WBI-1001 in
patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind
trial. Br J Dermatol 2012 Apr;166:853-60.
97. Papp K, Poulin Y, Barber K, Lynde C, Prinz JC, Berg M, Kerrouche N, Rives VP, Cost-effectiveness evaluation of clobetasol
propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysis.
J Eur Acad Dermatol Venereol 2012 Nov;26 911): 1407-14.
96. Tan J, O’Toole A, Zhang X, Dreno B, Poulin Y. Cultural and linguistic validation of acne-QoL in French.
J Eur Acad Dermatol Venereol 2011 Jul 29. Doi: 10.1111/j. 1468-3083.2011.04193.x. (Epub ahead of print)
95. Lynde CW, Gupta A, Guenther L, Poulin Y, Levesque A, Bissonnette R. A Randomized study comparing the combination of
nbUVB and Etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks
of Etanercept. J Dermatol Treat 2011 Jul 29 (Epub ahead of print)
94. Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas For The Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the
management of plaque psoriasis: overview. J Cut Med Surg 2011 Jul-Aug; 15 (4):210-219
93. Gordon. K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy ans safety of adalimumab in patients with moderate
to severe Psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL.
J Am acad Dermatol 2011 Jul 11 (Epub ahead of print)
92. Guenther L, Han C, Szapary P, Schenkel B, Poulin Y, Bourcier M, Ortonne JP, Sofen H. Impact of Ustekinumab on health-related
Quality of Life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol
Venereol 2011 Apr 27 (Epub ahead of print)
91. Poulin Y, Sanchez NP, Bucko A, Fowler J, Jarrat M, Kempers S, Kerrouche N, Dhuin JC, Kunynetz R. A 6-month maintenance
therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among severe acne vulgaris
patients:results of a randomized controlled trial. Br J Dermatol 2011 April 1 (Epub ahead of print)
90. Feldman SR, Tan J, Poulin Y, Dirschka T, Kerrouche N, Manna V. The efficacy of adapalene-benzoyl peroxide combination
increases with number of acne lesions. J Am Acad Dermatol 2011 March 23 (Epub ahead of print)
89. Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, Okun MM, Papp KA. Switching to adalimumab for psoriasis
Patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label
study. J Am Acad Dermatol 2011; Apr, 64 (4) 671-681.
88. Bissonnette R, Poulin Y, Guenther L, Lynde C, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab : a
randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2011 Feb 23 (Epub ahead of print)
87. Poulin Y, Papp KA, Wasel NR, Andrew R, Fraquelli E, Bernstein G, Chan D. A Canadian online survey to evaluate awareness
and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010 Dec;49(12) 1368-1375
86. Lynde C, Guenther L, Diepgen TL, Sasseville D, Poulin Y, Gulliver W, Agner T, Barber K, Bissonnette R, Ho V, Shear NH,
Toole J. Canadian hand dermatitis management guidelines. J Cut Med Surg 2010 Nov-Dec:14(6):267-284
85. Papp KA, Poulin Y, Bissonnette R, Bourcier M, Toyh D, Rosoph L, Poulin-Costello M, Setterfield M, Syrotuik J. Assessment of
the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
J Am Acad Dermatol 2010 Sep 16 (Epub ahead of print).
84. Tan JK, Tang J,Fung K, Gupta AK, Thomas RD, Sapra S, Lynde C, Poulin Y, Gulliver W, sebaldt RJ. Development and
validation of a scale fo acne scar severity (SCAR-S) of the face and trunk. J Cut Med Surg 2010 Jul-Aug; 14 94): 156-160
83. Papp K, Valenzuela F, Poulin Y, Bernstein G, Wasel N. Epidemiology of Moderate-to-Severe Plaque Psoriasis in
a Canadian Surveyed Population. J Cut Med Surg. Jul-Aug 2010;14(4):167-174
82. Hordinsky M, Fleischer A, Rivers JK, Poulin Y, Belsito D, Hultsch T. Efficacy and Safety of Pimecrolimus Cream 1%
in Mild-to-Moderate Hand Dermatitis: Double-Blind Trial. Dermatology 2010;221(1):71-77
81.- CANADIAN PSORIASIS GUIDELINES. CDA Website: WWW.DERMATOLOGY.CA Official publication to come.
80. Bissonnette R, Bolduc C. Poulin Y, Guenther L, Lynde CW, Maari C. Efficacy and safety of adalimumab in patients
with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol. 2010, May 20. .
79. Poulin Y, Thérien G. Drug-Induced Hepatitis and Lupus during Infliximab Treatment for Psoriasis : Case Report
and Literature Review. J Cut Med Surg 2010 Mar-Apr; 14(2):100-104.
78. Aubert J, Reiniche P, Fogel P, Poulin Y, Lui H, Lynde C, Shapiro J, Villemagne H, Soto P, Voegel JJ. Gene
expression profiling in psoriatic scalp hair follicles : clobetasol propionate shampoo 0,05% normalizes
psoriasis disease markers. J Eur Acad Dermatol Venereol 2010 Mar 23. Epub ahead of print.
77. Wexler D, Searles G, Landells I, Shear NH, Bissonnette R, Papp K, Poulin Y, Langley R, Gulliver WP.
Update on Alefacept safety. J Cut Med Surg. 2009. Dec;13 Suppl 3: S139-147
76. Poulin Y, Papp K, Bissonnette R, Barber K, Kerrouche N, Villemagne H. Clobetasol Propionate shampoo 0.05%
is efficacious and safe for long-term control of moderate scalp psoriasis. J Derm Treatment 2010 Feb 4
75. Poulin Y, Papp K, Bissonnette R, Guenther L, Tan J, Kerrouche N, Villemagne H; CalePso Study Team. Clobetasol
Propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. Cutis 2010 Jan;85(1):43-50
74. Wasel N, Poulin Y, Andrew R, Chan D, Fraquelli E, Papp K. A Canadian Self-Administered Online Survey
to Evaluate the Impact of Moderate-to-Severe Psoriasis among Patients. J Cutan Med Surg. 2009;13(6):294-302.
73. Poulin Y, Bourcier M. Practical aspects of prescribing a biologic. J Cutan Med Surg. 2009;13 Suppl 2:S93-S101.
72. Poulin Y, Langley RG, Teixeira HD, Martel MJ, Cheung S. Biologics in the treatment of psoriasis: clinical
and economic overview. J Cutan Med Surg. 2009 Sep-Oct;13 Suppl 2:S49-57.
71. Lynde CW, Poulin Y, Guenther L, Jackson C. The Burden of Psoriasis in Canada: Insights from the pSoriasis
Knowledge IN Canada (SKIN) Survey. J Cutan Med Surg. 2009 Sep-Oct;13(5):235-52.
70. Gold LS, Tan J, Cruz-Santana A, Papp K, Poulin Y, Schlessinger J, Gidner J,Liu Y, Graeber M;
Adapalene-BPO Study Group. A North American study of adapalene-benzoyl peroxide combination gel in the
treatment of acne. Cutis. 2009 Aug;84(2):110-6.
69. Poulin Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to
etanercept. J Cut Med Surg. 2009 Jul-Aug;13(4):221-5
68. Tan JK, Balagurusamy M, Fung K, Gupta AK, Richard Thomas D, Sapra S, Lynde C, Poulin Y, Gulliver W,
Sebaldt RJ. Effect of quality of life impact and clinical severity on adherence to topical acne treatment.
J Cutan Med Surg. 2009.Jul-Aug;13(4):204-8
67. Chan B, Hales B, Shear N, Ho V, Lynde C, Poulin Y, Mittmann N. Work-related lost productivity and its economic
impact on canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009 Jul-Aug;13(4):192-7
66. Tan J, Thomas R, Wang B, Gratton D, Vender R, Kerrouche N, Villemagne H; CalePso Study Team. Short-contact
clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis.
Cutis. 2009 Mar;83(3):157-64
65. Bissonnette R, Poulin Y, Bolduc C, Maari C, Provost N, Syrotuik J, Poulin-Costello CM, Nigen S. Etanercept
in the treatment of palmoplantar pustulosis. J Drugs Dermatol. Oct 2008; 7 (10) 940-946
64. Tan JK, Li Y, Fung K, Gupta AK, Thomas DR, Sapra S, Lynde C, Poulin Y, Gulliver W, Sebaldt RJ.
Divergence of demographic factors associated with clinical severity compared with quality of life impact in acne.
J Cutan Med Surg. 2008 Sep-Oct;12 (5):235-42
63. Jemec BGE, Ganslandt C, Ortonne JP , Poulin Y, Burden AD, Unamuno P, Berne B, Figueiredo A, Austad J.A new scalp
formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp
psoriasis: A randomized, double-blind, controlled trial. J Am Acad Dermatol. Sept 2008;59: 455-463
62. Tan JKL, Tang J, Fung K, Gupta AK, Thomas D R, Sapra S, Lynde C, Poulin Y, Gulliver W, Sebaldt RJ.
Prevalence and Severity of Facial and Truncal Acne in a Referral Cohort. J Drugs in Derm, June 2008, vol 7 (6):553-6
61. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S,
Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23
Monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled
trial (PHOENIX 2). Lancet. 2008 May 17;371(9625):1675-84.
60. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1
study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients
with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Lancet. 2008 May 17;371(9625):1665-74.
59. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A;
CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of
adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
Br J Dermatol. 2008 Mar;158(3):558-66.
58. Poulin Y, Bissonnette R, Juneau C, Cantin K, Drouin R, Poubelle PE. XP-828L in the treatment of mild to moderate
psoriasis: randomized, double-blind, placebo-controlled study. Altern Med Rev. 2007 Dec;12(4):352-9
57. Tan JK, Tang J, Fung K, Gupta AK, Thomas DR, Sapra S, Lynde C, Poulin Y, Gulliver W, Sebaldt RJ.
Development and validation of a comprehensive acne severity scale. J Cutan Med Surg. 2007 Nov-Dec;11(6):211-216.
56. Tan JK, Thomas DR, Poulin Y, Maddin F, Tang J. Efficacy of imiquimod as an adjunct to cryotherapyfor actinic keratoses.
J Cutan Med Surg. 2007 Nov-Dec;11(6):195-201.
55. Poulin Y. Efalizumab for moderate to severe plaque psoriasis: A Clinical Review. HELIX review Series. Issue 2, 2007.
54. Gupta AK, Lynde CW, Poulin Y, Smith K, Lewis R, Zip C. Position Statement for Isotretinoin. J Cut Med Surg 2007 may-Jun
;11; 123-124.
53. Tyring S, Gordon KB, Pouin Y, Langley RG, Gottlieb AB, Dunn M, Jarheis A. Long-term Safety and Efficacy
of 50 mg of Etanercept Twice Weekly in Patients with Psoriasis. Arch Dermatol. June 2007;143: 719-726
52. Poulin Y, Gupta AK, Amiss JD. Efficacy of Etanercept in the Management of Plaque Psoriasis and Psoriatic Arthritis.
J Cut Med Surg. April 2007;11.S1: S14 - S22.
51. Draelos ZD, Carter E, Maloney M, Elewski B, Poulin Y, Lynde C, Garrett S. Two randomized studies demonstrate the efficacy
and safety of dapsone gel, 5% fo the treatment of acne vulgaris. J Am Acad Dermatol. March 2007; 56: 439-447.
50. Vender RB, Lynde CW, Poulin Y. Prevalence and epidemiology of onychomycosis. J Cutan Med Surg. 2006 Dec;10 Suppl
2:S28-33
49. Gupta AK, Poulin Y, Lynde CW. Canadian perspectives on antifungal treatment for onychomycosis. J Cutan Med Surg. 2006
Dec;10 Suppl 2:S34-8.
48. Poulin Y, Thomas R, Gupta AK. Brief treatment guide for onychomycosis. J Cutan Med Surg. 2006 Dec;10 Suppl 2:S39-43
47. Poulin Y, Bissonnette R, Juneau C, Cantin K, Drouin R, Poubelle PE. XP-828l in the Treatment of Mild to
Moderate Psoriasis: Randomized, Double-Blind, Placebo-Controlled Study. J Cutan Med Surg. 2006 Sep-Oct;10(5):241-8.
46. Poulin Y, Papp KA, Carey W, Gulliver W, Gupta AK. A favourable benefit/risk ratio with efalizumab: A review of the clinical
evidence. J Cutan Med Surg. 2006 Apr 20.
45. Langley RG, Ho V, Lynde C, Papp KA, Poulin Y, Shear N, Toole J, Zip C. Recommendations for incorporating
biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
J Cutan Med Surg. 2006 Apr 20
44. Papp KA, Ho V, Langley R, Lynde C, Poulin Y, Shear N, Toole J, Zip C. Strategies for optimizing
treatment with efalizumab in moderate to severe psoriasis. J Cutan Med Surg. 2006 Apr 20
43. Bissonnette R, Papp K, Poulin Y, Lauzon G, Aspeslet L, Huizinga R, Mayo P,Foster RT, Yatscoff RW,
Maksymowych WP; ISA247 Psoriasis Study Group. A randomized, multicenter, double-blind, placebo-controlled
phase 2 trial of ISA247 in patients with chronic plaque psoriasis.J Am Acad Dermatol. 2006 Mar;54(3):472-8.
42.Kaufmann R, Bieber T, Helgesen AL, Andersen BL, Luger T, Poulin Y, Al-Hafidh J, Paul C; the multicentre
investigator group. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.Allergy. 2006 Mar;61(3):375-81. 41.Thiboutot D, Pariser DM, Egan N, Flores J, Herndon JH Jr, Kanof NB, Kempers SE, Maddin S, Poulin YP,
Wilson DC, Hwa J, Liu Y, Graeber M; Adapalene Study Group. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial.
J Am Acad Dermatol. 2006 Feb;54(2):242-50.
40. Poulin Y, Pouliot Y, Lamiot E, Aattouri N, Gauthier SF. Safety and efficacy of a milk-derived extract
in the treatment of plaque psoriasis: an open-label study. J Cutan Med Surg. 2005 Dec;9(6):271-5.
39.Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, Murray E, Papp K, Poulin Y, Zip C.
Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian
Psoriasis Expert Panel. J Cutan Med Surg. Sept-Oct 2005;8: 321-337.
38. Poulin Y. Practical Approach to the Hormonal Treatment of Acne. J Cut Med Surg. 2005 Mar 31.
37. Langley R, Gupta AK, Poulin Y, Guenther L, Barber K, Gulliver W, Lynde C. The Use of Alefacept in the
Treatment of Psoriasis. J Cut Med Surg. August 2004;8: S14-S18.
36.Lui H, Langley R, Poulin Y, Gupta AK, Carey W, Guenther L, Searles G, Toole J, Lnde C, Gulliver W,
Barber K. Incorporating Biologics into the Treatment of Psoriasis. J Cut Med Surg. August 2004;8: S8-S13
35.Gupta AK, Langley R, Poulin Y, Lui H, Searles G, Carey W, Toole J, Inniss K. Pathogenesis of Psoriasis and
Current Challenges. J Cut Med Surg. August 2004;8: S3-S7
34.Poulin Y. Psoriasis Today: A new Paradigm. J Cut Med Surg . August 2004;8: S1-S2
33.Lowe N, Gifford M, Tanghetti E, Poulin Y, Goldman M, Tse Y, Yamauchi P, Rosenzweig H, Kang S.
Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin:
a multicenter, double-blind, randomized, parallel-group study. J Cosmet Laser Ther. 2004;6(2):79-85.
32. Jarrat M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V: Clobetasol Propionate Shampoo 0.05%: A new
option to treat Patients with Moderate to Severe Scalp Psoriasis. J Drugs Dermatol July/August 2004; 3 (4): 367-373.
31. Lowe NJ, Gifford M, Tanghetti E, Poulin YP, Goldman M, Tse Y, Yamauchi P, Rosenzweig H, Kang S.
Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged
facial skin: a multicenter, double-blind, randomized, parallel-group study. J Cosmet Laser Ther 2004;6:79-85
30. Tan J, Langley R for the Canadian Open-label multicentre Study. Safety and Efficacy of Tacrolimus ointment
0.1% in atopic dermatitis-a Canadian open-label Multicentre study. Submitted for publication 9march 2004.
29.Tan J, Thomas R, Sapra S, Poulin Y, Lynde C, Gulliver W, Sebaldt R. Baseline demographics:
interim analysis of Canadian Acne Epidemiological Survey. JEADV2003;17(supp 3):145(abstract).
28.Tan J, Thomas R, Sapra S, Poulin Y, Lynde C, Gulliver W, Sebaldt R. An epidemiological and
outcomes survey of Canadian Acne Patients. JEADV2003;17(supp 3):113(abstract).
27. Nigen S, Poulin Y, Rochette L, Levesque MH. Pyodermatitis-Pyostomatitis Vegetans : Two Cases and Review of the literature.
J Cut Med Surg 2003; 7: 250-255.
26. Dupéré, A. , Poulin, Y.: Facial lipoatrophy following systemic lupus erythematosus. J Cut Med Surg 2003: 7; 232-235.
25. Dessureault J, Poulin Y, Bourcier M, Gagne E. Olmsted Syndrome- Palmoplantar and Periorificial Keratodermas: Association
with Malignant Melanoma. J Cutan Med Surg 2003: 7; 236-242.
24.Lemay A, Poulin Y. Oral contraceptives as anti-androgenic treatment of acne. J.Obstet Gynaecol Can. 2002 Jul;24(7):559-67
23.Poulin Y: Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): A new formulation for the
treatment of psoriasis. Skin Therapy Lett. 2002 Jun;7(6):1-3
22. Webster G, Guenther L, Poulin Y, Solomon B, Loven K, Lee J. Assessing the Cost-Effectiveness of
Tazarotene 0.1% Gel Versus Adapalene 0.1% Gel in Patients with Facial Acne Vulgaris. Clinical Therapeutics. July 2002.
21. Poulin Y. Psoriasis: Current Therapy. J Cutan Med Surg. 2002 May-Jun; 6 (3 Suppl)
20. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y.Topical treatment of actinic keratoses
with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002 Jan;146(1):94-100.
19. Webster GF, Guenther L, Poulin YP, Solomon B, Loven K: A Multicenter, Double-Blind, Randomized
Comparison of the Efficacy and Tolerability of Treating Facial Acne Vulgaris Once Daily with
Tazarotene 0.1% gel or Adapalene 0.1% gel. CUTIS. Feb 2002; 69: 4-11.
18. Tan JK, Girard C, Krol A, Murray HE, Papp KA, Poulin Y, Chin DA, Jeandupeux D.
Randomized Placebo-controlled Trial of Metronidazole 1% Cream with Sunscreen SPF 15 in Treatment
of Rosacea. J Cutan Med Surg. 2002 May 13:
17. Douglas W.S. , Poulin Y. , Decroix J., Ortonne J.P. , Mrowietz U. , Gulliver W. , Krogstad A.L. , Larsen L., Iglesias S F.G. ,
Buckley C. , Bibby A.J. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy
with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Dermato-Venereologica vol. 82, No 2, 2002: 131-135
16. Poulin, Y, Guenther, L , Pariser, DM: A Comparison of Tazarotene 0.1 % Gel Once Daily plus Mometasone
Furoate 0.1 % Cream Once Daily Versus Calcipotriene 0.005 % Ointment Twice Daily in the Treatment of
Plaque Psoriasis. Clin Ther. 2000 Oct; 22 ( 10 ): 1225 – 1238
15. Lemay, A, Poulin, Y: Hyperandrogenism: Objective clinical Evaluation of Dermatological Manifestations. SOGC Journal.
14. Alain J., Poulin Y., Cloutier R., Gagné, E., Baril, J. Calciphylaxis: Seven New Cases.
Journal of Cutaneous Medicine and Surgery 2000 Oct; 4 ( 4 ): 213 – 218.
13. Maddin, WS, Landells, IDR., Poulin, Y, Searles G., Smith,Kevin C., Tan, JKL, Toole, J, Zip, C, Degreef, H:
Treatment of Acne Vulgaris and Prevention of Acne Scarring: Canadian Consensus Guidelines.
J Cut Med Surg. Vol. 4, Suppl. 1, June 2000, pp S4-1 - S4-13
12. Poulin, Y. Tazarotene 0. 1 % gel in combination with Mometasone furoate cream in plaque
Psoriasis: a photographic tracking study. CUTIS. January 1999; 63: 41 - 48.
11. Lebwohl, M, Poulin, Y: Tazarotene in combination with topical corticosteroids.
J.Am.Acad.Dermatol. October 1998; 39-. S139 - S143
10. Poulin, Y.: Balanites et balanoposthites. Le Médecin du Québec. August 1998, vol.33-.pp.34-39
09 . Poulin, Y.: Tazarotene plus Steroid effective Psoriasis Treatment. The Chronicle of Skin &
Allergy . February 1998, pp l7-18.
08. Poulin, Y.: Le syndrome de la Rosacée. Actualité Médicale vol. 1 8 no.24, 25 juin 1997, pp.20-22
07. Poulin Y, : Piqûres et morsures d'insectes: diagnostic et traitement. Médecine sport.Actualité médicale,
vol.17 no.20, 22mai l996,pp7-8.
06. Poulin Y.: Callosités, cors et verrues plantaires-. diagnostic et traitement. Médecine sport.
Actualité médicale, octobre 1993, p.p. 14-15
05. Poulin Y., Perry H.O., Muller S.A.: Pemphigus Vulgaris: Results of treatment with gold as a steroid-sparing
agent in a series of thirteen patients. J. Am. Acad. Dermatol 11 : 851-857, Nov. 1984
04. Poulin Y., Perry H.O., Muller S.A.-. The Olsmted syndrome- Palmo-plantar and Periorificial Keratoderma.
J. Am. Acad. Dermatol 4: 600-610, 1984.
03. Poulin Y., Girard C. Epidermolysis Bullosa Acquisita. Can. Derm. Ass. Bull. Vol. 1 no. 20, Jun. 1983.
02. Poulin Y., Bellefeuille J.: Les anti- histaminiques de type bloqueurs H 1. Un. Med. Can. 112: 78-79, Jan. 1983.
01. Shapcott D. Fisch C., Poulin Y.: Pitfalls in the use of serum iron concentration in diagnosis of anaemia. Clin. Chem. June
1980;7: 1104-105.

Source: http://crdq.ca/files/Publications.pdf